Ensysce Biosciences, Inc.

NasdaqCM:ENSC Stock Report

Market Cap: US$9.3m

Ensysce Biosciences Management

Management criteria checks 4/4

Ensysce Biosciences' CEO is D. Kirkpatrick, appointed in Jan 2009, has a tenure of 15.83 years. total yearly compensation is $508.58K, comprised of 79.6% salary and 20.4% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $1.07K. The average tenure of the management team and the board of directors is 4.9 years and 4.3 years respectively.

Key information

D. Kirkpatrick

Chief executive officer

US$508.6k

Total compensation

CEO salary percentage79.6%
CEO tenure15.8yrs
CEO ownership0.01%
Management average tenure4.9yrs
Board average tenure4.3yrs

Recent management updates

This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate

Nov 14
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate

Recent updates

This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate

Nov 14
This Is Why Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Looks Appropriate

Ensysce Biosciences secures $8M convertible note financing

Jul 01

CEO Compensation Analysis

How has D. Kirkpatrick's remuneration changed compared to Ensysce Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$12m

Dec 31 2023US$509kUS$405k

-US$11m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$20m

Mar 31 2023n/an/a

-US$26m

Dec 31 2022US$623kUS$393k

-US$25m

Sep 30 2022n/an/a

-US$30m

Jun 30 2022n/an/a

-US$38m

Mar 31 2022n/an/a

-US$31m

Dec 31 2021US$288kUS$174k

-US$30m

Sep 30 2021n/an/a

-US$19m

Jun 30 2021n/an/a

-US$99k

Mar 31 2021n/an/a

US$172k

Dec 31 2020US$156kUS$156k

US$57k

Compensation vs Market: D.'s total compensation ($USD508.58K) is about average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: D.'s compensation has been consistent with company performance over the past year.

CEO

D. Kirkpatrick (67 yo)

15.8yrs

Tenure

US$508,575

Compensation

Dr. D. Lynn Kirkpatrick, Ph.D. is a Co Founder of ProlX Pharmaceuticals Corporation and has been its Chief Executive Officer since 1999. She has been Chief Executive Officer of Ensysce Biosciences, Inc. si...

Leadership Team

NamePositionTenureCompensationOwnership
D. Kirkpatrick
President15.8yrsUS$508.58k0.011%
$ 1.1k
David Humphrey
CFO, Secretary & Treasurer3.8yrsUS$441.95k0.0015%
$ 139.5
Geoffrey Birkett
Chief Commercial Officer6.1yrsUS$392.35k0%
$ 0
Jeffrey Millard
Chief Operating Officer1.1yrsno datano data
William Schmidt
Chairman of Clinical Advisory Board & Chief Medical Officer8.8yrsno datano data
Linda Pestano
Chief Development Officer3.1yrsno data0%
$ 0

4.9yrs

Average Tenure

58yo

Average Age

Experienced Management: ENSC's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
D. Kirkpatrick
President7.5yrsUS$508.58k0.011%
$ 1.1k
William Schmidt
Chairman of Clinical Advisory Board & Chief Medical Officer2.2yrsno datano data
Robert Gower
Independent Chairman of the Board16.8yrsUS$47.60k0.88%
$ 81.7k
Lee Rauch
Independent Director2.8yrsUS$29.17k0%
$ 0
Andrew Benton
Independent Director4.9yrsUS$30.10k0.14%
$ 13.4k
Richard Dart
Member of the Clinical Advisory Boardno datano datano data
Steven Martin
Independent Director4.3yrsUS$32.92k0%
$ 0
Lynn Webster
Member of the Clinical Advisory Boardno datano datano data
Hui-Chung Chang
Independent Director8.8yrsUS$30.10k0.23%
$ 20.9k
Jeffrey Gudin
Member of the Clinical Advisory Boardno datano datano data
Curtis Rosebraugh
Independent Director3.4yrsUS$25.42k0%
$ 0
Adam Levin
Independent Director3.4yrsUS$27.92k0%
$ 0

4.3yrs

Average Tenure

67.5yo

Average Age

Experienced Board: ENSC's board of directors are considered experienced (4.3 years average tenure).